8-K: Telomir Faces Nasdaq Non-Compliance for Delayed Annual Meeting

Telomir Pharmaceuticals received a Nasdaq notice for failing to hold its annual shareholder meeting within the required timeframe, but expects to regain compliance.

Summary

• Telomir Pharmaceuticals, Inc. (the "Company") received a written notice from The Nasdaq Stock Market LLC on January 8, 2026.
• The notice indicates non-compliance with Nasdaq Listing Rule 5620(a), which mandates holding an annual meeting of shareholders within twelve months of the fiscal year end.
• The Company had planned its annual meeting for December 30, 2025, after submitting a preliminary proxy statement to the SEC on November 20, 2025.
• The preliminary proxy statement remains under review by the SEC, which has delayed the annual meeting.
• The notice does not result in immediate delisting and has no current effect on the trading of the Company's common stock.
• Telomir has until February 23, 2026, to submit a plan to regain compliance with Nasdaq Listing Rule 5620(a).
• The Company expects to promptly hold its annual meeting and regain compliance once the SEC review process is complete.
• Telomir intends to timely submit its compliance plan and take all necessary steps to regain compliance within the applicable cure period.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the non-compliance notice from Nasdaq, which indicates a failure to meet a regulatory requirement. However, the impact is mitigated by the fact that delisting is not immediate, the company has a clear plan to regain compliance, and the delay is attributed to an external factor (SEC review).

Positives

• The Nasdaq notice does not result in the immediate delisting of the Company's securities.
• The notice has no current effect on the listing or trading of the Company's common stock on the Nasdaq Capital Market.
• The Company has communicated with Nasdaq and intends to submit a compliance plan by February 23, 2026.
• Management expects to promptly hold the annual meeting and regain compliance once the SEC review is complete.

Negatives

• The Company is not in compliance with Nasdaq Listing Rule 5620(a) due to the delay in holding its annual meeting.
• The preliminary proxy statement for the annual meeting, submitted on November 20, 2025, is still under SEC review, causing the delay.
• Failure to regain compliance could ultimately lead to delisting from Nasdaq.

Risks

• The Company's ability to submit a plan to regain compliance satisfactory to Nasdaq.
• The Company's ability to hold an annual meeting in a timely manner.
• Other risks and uncertainties set forth in the Company's reports filed with the SEC.

Future Outlook

The Company expects to promptly hold its annual meeting of shareholders and regain compliance with Nasdaq Listing Rule 5620(a) following the completion of the SEC review process. It intends to timely submit its compliance plan and take all necessary steps within the applicable cure period.

Management Comments

• "The Company has communicated with Nasdaq regarding the circumstances related to the timing of its annual meeting in connection with its compliance plan."
• "Following completion of the SEC review process, the Company expects to promptly hold its annual meeting of shareholders and regain compliance with Nasdaq Listing Rule 5620(a)."
• "The Company intends to timely submit its compliance plan and to take all necessary steps to regain compliance within the applicable cure period."

Industry Context

This announcement highlights the strict regulatory environment for publicly traded companies, where adherence to listing rules, such as timely annual shareholder meetings, is crucial for maintaining market access. Delays in SEC review processes can impact a company's ability to meet these obligations, a common challenge across various industries.

Stakeholder Impact

• Shareholders: The delay in the annual meeting means a delay in shareholder engagement and voting on company matters. There is also a potential, albeit not immediate, risk of delisting if compliance is not regained.
• Regulatory Bodies (Nasdaq, SEC): The Company is actively engaging with Nasdaq to address the non-compliance and awaiting SEC review completion.

Next Steps

• Submit a plan to regain compliance with Nasdaq Listing Rule 5620(a) by February 23, 2026.
• Hold the annual meeting of shareholders promptly after the SEC completes its review of the preliminary proxy statement.
• Take all necessary steps to regain compliance within the applicable cure period granted by Nasdaq.

Key Dates

Recommendation

While the Nasdaq non-compliance notice is a negative development, it does not result in immediate delisting, and the company has a stated plan to regain compliance, attributing the delay to ongoing SEC review. This suggests a procedural issue rather than a fundamental operational or financial problem. Investors should monitor the company's progress in submitting its compliance plan and holding the annual meeting, but the current situation does not warrant an immediate 'sell' given the outlined path to resolution. A 'buy' is not justified due to the regulatory uncertainty.

Keywords

Nasdaq, Listing Rule 5620(a), Annual Meeting, SEC Review, Compliance Plan, Delisting Risk, Corporate Governance, TELO